ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Bo Wei
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fan, X.
Right arrow Articles by Ruan, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fan, X.
Right arrow Articles by Ruan, Y.
Related Collections
Right arrow Extracorporeal circulation

Ann Thorac Surg 2006;81:896-901
© 2006 The Society of Thoracic Surgeons

Original article: Cardiovascular

Lung Perfusion With Clarithromycin Ameliorates Lung Function After Cardiopulmonary Bypass

Xiangming Fan, MD * , Yinglong Liu, MD, Qiang Wang, MD, Cuntao Yu, MD, Bo Wei, MD, Yingmao Ruan, MD

Department of Surgery, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Accepted for publication September 15, 2005.

* Address correspondence to Dr Fan, Department of Surgery, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China (Email: fanxiangming{at}126.com).

BACKGROUND: Macrolides antibiotics may affect neutrophil functions that correlate with the inflammation induced by cardiopulmonary bypass. Our study observed the protective effect of clarithromycin on inflammatory lung injury after cardiopulmonary bypass.

METHODS: Twelve adult sheep were randomly divided into two groups. After cardiopulmonary bypass was established, the lung was perfused through the pulmonary artery with either dextran solution (30 mL/kg) in the control group (n = 6) or dextran solution added to clarithromycin (10 mg/kg) in the experimental group (n = 6). Bypass was withdrawn after 90 minutes. Pulmonary function was determined and inflammatory factors were analyzed. Apoptotic neutrophils in the lung were assayed and lung biopsies were also performed.

RESULTS: Pulmonary vascular resistance (102.2 ± 14.0 dyne.s.cm-5) was lower in the experimental group compared with the control group (202.6 ± 47.3 dyne.s.cm-5, p < 0.01) whereas the oxygen index was higher in the experimental group (p < 0.05). Plasma myeloperoxidase in the experimental group (0.015 ± 0.006 U/L) was lower than that in the control group (0.029 ± 0.007 U/L, p < 0.01). Plasma interlukin-8 (0.18 ± 0.04 ug/L) and tumor necrosis factor (1.00 ± 0.13 ug/L) in the experimental group were lower than in the control group (0.39 ± 0.09 ug/L, 1.55 ± 0.35 ug/L, p < 0.01). Histologic analyses showed intra-alveolar hemorrhage and neutrophil accumulation in the control group, whereas there were no significant changes in the experimental group. The apoptosis rate of accumulated neutrophils was significantly lower in the control group (p < 0.01).

CONCLUSIONS: Lung perfusion with hypothermic protective solution containing clarithromycin distinctly inhibits inflammatory responses caused by cardiopulmonary bypass and ameliorates lung function.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The Society of Thoracic Surgeons.